


CDCA1-A11-9-123
a
CDCA1-A11-9-105
b
CDCA1-A11-9-419
c
CDCA1-A11-9-219
d
CDCA1-A11-9-439
e
CDCA1-A11-9-343
f
CDCA1-A11-9-21
g
CDCA1-A11-9-157
h
CDCA1-A11-9-244
i
CDCA1-A11-9-213
j
CDCA1-A11-9-335
k
CDCA1-A11-9-25
l
+
—
1
2
3
4
5
6
7
8
TNTC

FIG. 1-1


CDCA1-A11-10-339
CDCA1-A11-10-452
CDCA1-A11-10-400
CDCA1-A11-10-289
CDCA1-A11-10-203
CDCA1-A11-10-156
m
n
o
p
q
r
+
—
1
2
3
4
5
6
7
8



CDCA1-A11-10-340
CDCA1-A11-10-106
CDCA1-A11-10-358
CDCA1-A11-10-391
s
t
u
v
+
—
1
2
3
4
5
6
7
8

FIG. 1-2





a
CDCA1-A11-9-123 #7
IFN-γ(pg/ml)
2000
1600
1200
800
400
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
b
CDCA1-A11-9-105 #8
IFN-γ(pg/ml)
600
500
400
300
200
100
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
c
CDCA1-A11-9-419 #1
IFN-γ(pg/ml)
8000
6000
4000
2000
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
d
CDCA1-A11-9-219 #4
IFN-γ(pg/ml)
2000
1500
1000
500
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
e
CDCA1-A11-9-439 #2
IFN-γ(pg/ml)
2000
1600
1200
800
400
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
f
CDCA1-A11-9-157 #3
IFN-γ(pg/ml)
1000
800
600
400
200
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 2-1

g


CDCA1-A11-9-25 #4
IFN-γ(pg/ml)
1400
1200
1000
800
600
400
200
0
5.0
2.5
1.3
0.6
R/S ratio
+
-

h


CDCA1-A11-10-339 #3
IFN-γ(pg/ml)
1000
800
600
400
200
0
5.0
2.5
1.3
0.6
R/S ratio
+
-

i





CDCA1-A11-10-358 #2
IFN-γ(pg/ml)
1000
800
600
400
200
0
5.0
2.5
1.3
0.6
R/S ratio
+
-

FIG. 2-2

a


CDCA1-A11-9-105 #8
IFN-γ(pg/ml)
800
700
600
500
400
300
200
100
0
(+)
(-)
5.0
2.5
1.3
0.6
R/S ratio

b


CDCA1-A11-9-419 #1
IFN-γ(pg/ml)
2500
2000
1500
1000
500
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

c



CDCA1-A11-9-219 #4
IFN-γ(pg/ml)
3000
2500
2000
1500
1000
500
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 3



CDCA1-A11-9-219
IFN-γ (pg/ml)
2000
1600
1200
800
400
0
2.2
1.1
0.6
0.3
0.1
0.07
R/S ratio
A11
A11 + CDCA1
CDCA1

FIG. 4





CDCA1-A33-9-43
a
CDCA1-A33-9-123
b
CDCA1-A33-9-108
c
CDCA1-A33-9-261
d
CDCA1-A33-9-105
e
CDCA1-A33-10-10
f
CDCA1-A33-10-260
g
CDCA1-A33-10-122
h
+
—
1
2
3
4
5
6
7
8

FIG. 5


a


CDCA1-A33-9-43 #2
IFN-γ(pg/ml)
350
300
250
200
150
100
50
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

b


CDCA1-A33-9-123 #1
IFN-γ(pg/ml)
180
150
120
90
60
30
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

c


CDCA1-A33-10-10 #8
IFN-γ(pg/ml)
350
300
250
200
150
100
50
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

d



CDCA1-A33-10-260 #5
IFN-γ(pg/ml)
700
600
500
400
300
200
100
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 6



a
CDCA1-A33-9-43 #2
IFN-γ(pg/ml)
5000
4000
3000
2000
1000
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
b
CDCA1-A33-9-123 #1
IFN-γ(pg/ml)
6000
5000
4000
3000
2000
1000
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 7



CDCA1-A33-9-43
600
500
400
300
200
100
0
IFN-γ (pg/ml)
14.1
7.1
3.5
1.8
0.9
0.4
R/S ratio
A33
A33 + CDCA1
CDCA1

FIG. 8



CDCA1-A03-9-219
CDCA1-A03-10-400
CDCA1-A03-10-257
CDCA1-A03-9-343
a
b
c
d
+
—
1
2
3
4
5
6
28
20
4
4
TNTC
1
3
0
3
4
0
0
TNTC
1
22
1
41
5
129
27
141
0
1
2
2
1
38
2
2
3
1
5
10
1
2
3
20
21
2
4
5
2
40
45
2
3
2
0

FIG. 9





a
CDCA1-A03-9-219 #3
IFN-γ(pg/ml)
3000
2500
2000
1500
1000
500
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
b
CDCA1-A03-10-400 #1
IFN-γ(pg/ml)
6000
5000
4000
3000
2000
1000
0
+
-
5.0
2.5
1.3
0.6
R/S ratio
c
CDCA1-A03-10-257 #2
IFN-γ(pg/ml)
200
150
100
50
0
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 10

a


CDCA1-A03-9-219 #3
600
500
400
300
200
100
0
IFN-γ(pg/ml)
+
-
5.0
2.5
1.3
0.6
R/S ratio

b


CDCA1-A03-10-400 #1
2500
2000
1500
1000
500
0
IFN-γ(pg/ml)
+
-
5.0
2.5
1.3
0.6
R/S ratio

c




CDCA1-A03-10-257 #2
250
200
150
100
50
0
IFN-γ(pg/ml)
+
-
5.0
2.5
1.3
0.6
R/S ratio

FIG. 11

a


CDCA1-A03-9-219
IFN-γ (pg/ml)
700
600
500
400
300
200
100
0
7.6
3.8
1.9
0.9
0.5
0.2
R/S ratio
A03
A03 + CDCA1
CDCA1

b



CDCA1-A03-10-400
IFN-γ (pg/ml)
160
140
120
100
80
60
40
20
0
1.4
0.7
0.4
0.2
0.1
0.04
R/S ratio
A03
A03 + CDCA1
CDCA1

FIG. 12